Candel therapeutics announces oral presentation during the 5th glioblastoma drug development summit with update on phase 1b clinical trial of can-3110 in recurrent high-grade glioma

Needham, mass., march 28, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the presentation of updated data from an ongoing phase 1b clinical trial of its herpes simplex virus-1 (hsv-1) replication-competent viral immunotherapy candidate, can-3110, in patients with rhgg that has recurred after standard of care (soc) treatment. the data were presented today during the 5th glioblastoma drug development summit in boston, massachusetts.
CADL Ratings Summary
CADL Quant Ranking